Recombinant gonadotropins are experiencing rapid development, yet urine-derived raw materials still hold unique value.

The technology for recombinant HCG and HMG-based formulations has undergone continuous iterative upgrades, exerting certain competitive pressure on the traditional urine-derived active pharmaceutical ingredient (API) market. However, in specific clinical application scenarios, urine-derived active proteins still possess irreplaceable application advantages.